Rohan Mata's questions to Crinetics Pharmaceuticals Inc (CRNX) leadership • Q2 2025
Question
An analyst on behalf of Rohan Mata from Oppenheimer & Co. Inc. asked how Crinetics plans to manage the progression toward NDA submission and labeling discussions for adamelin, given the different timelines for the adult and pediatric CAH trials.
Answer
Chief Medical & Development Officer Dana Pizzuti stated that the company views the adult and pediatric programs as distinct submissions. She explained that they will not hold one for the other; the adult Phase III trial is expected to finish first and will be submitted. Following a successful outcome, the company would then submit a supplement or amendment to add the pediatric data and indication.